Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.

Eichholz A, Ferraldeschi R, Attard G, de Bono JS.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):68-75. doi: 10.1016/j.mce.2011.09.038. Epub 2011 Oct 1. Review.

PMID:
21986558
2.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

3.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
4.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
5.

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.

Salem M, Garcia JA.

Curr Oncol Rep. 2011 Apr;13(2):92-6. doi: 10.1007/s11912-011-0153-4. Review.

PMID:
21243537
6.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS.

J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.

7.

Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.

Zhu H, Garcia JA.

Curr Oncol Rep. 2013 Apr;15(2):105-12. doi: 10.1007/s11912-013-0300-1. Review.

PMID:
23371447
8.

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.

Stein MN, Patel N, Bershadskiy A, Sokoloff A, Singer EA.

Asian J Androl. 2014 May-Jun;16(3):387-400. doi: 10.4103/1008-682X.129133. Review.

9.

Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.

Bedoya DJ, Mitsiades N.

Expert Rev Anticancer Ther. 2012 Jan;12(1):1-3. doi: 10.1586/era.11.196. No abstract available.

PMID:
22149426
10.

Targeting CYP17: established and novel approaches in prostate cancer.

Yap TA, Carden CP, Attard G, de Bono JS.

Curr Opin Pharmacol. 2008 Aug;8(4):449-57. doi: 10.1016/j.coph.2008.06.004. Epub 2008 Jul 28. Review.

PMID:
18619560
11.

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

Ang JE, Olmos D, de Bono JS.

Br J Cancer. 2009 Mar 10;100(5):671-5. doi: 10.1038/sj.bjc.6604904. Epub 2009 Feb 17. Review.

12.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ.

J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16.

13.

Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.

Pal SK, Twardowski P, Josephson DY.

Maturitas. 2009 Oct 20;64(2):61-6. doi: 10.1016/j.maturitas.2009.08.004. Epub 2009 Sep 5. Review.

PMID:
19733987
14.

Agents that target androgen synthesis in castration-resistant prostate cancer.

Ferraldeschi R, de Bono J.

Cancer J. 2013 Jan-Feb;19(1):34-42. doi: 10.1097/PPO.0b013e31827e0b6f. Review.

PMID:
23337755
15.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
16.

Targeting continued androgen receptor signaling in prostate cancer.

Massard C, Fizazi K.

Clin Cancer Res. 2011 Jun 15;17(12):3876-83. doi: 10.1158/1078-0432.CCR-10-2815. Review.

17.

Abiraterone in prostate cancer: a new angle to an old problem.

Stein MN, Goodin S, Dipaola RS.

Clin Cancer Res. 2012 Apr 1;18(7):1848-54. doi: 10.1158/1078-0432.CCR-11-1805. Epub 2012 Mar 26. Review.

18.

The role of enzalutamide in the treatment of castration-resistant prostate cancer.

Rawlinson A, Mohammed A, Miller M, Kunkler R.

Future Oncol. 2012 Sep;8(9):1073-81. doi: 10.2217/fon.12.99. Review.

PMID:
23030482
19.

[Castration resistant prostate cancer 2011].

Miller K.

Aktuelle Urol. 2011 Mar;42(2):95-102. doi: 10.1055/s-0031-1271399. Epub 2011 Mar 24. Review. German.

PMID:
21437832
20.

Changing therapeutic paradigms in castrate-resistant prostate cancer.

Zivi A, Massard C, De-Bono J.

Clin Genitourin Cancer. 2010 Dec 1;8(1):17-22. doi: 10.3816/CGC.2010.n.003. Review.

PMID:
21208851

Supplemental Content

Support Center